cdc28 Antibody

What is cdc28 Antibody and what organism does it target?

Cdc28 Antibody (G-7) is a mouse monoclonal IgG1 kappa light chain antibody specifically designed to detect the Cdc28 protein of Saccharomyces cerevisiae origin. This antibody has been extensively characterized for its specificity to the master cell cycle regulator in budding yeast. The antibody recognizes epitopes specific to the Cdc28 protein structure, making it valuable for studying cell cycle regulation in yeast models . Structurally, it consists of a standard immunoglobulin framework with specific antigen-binding regions tailored to recognize Cdc28 protein conformations, enabling precise detection in complex cellular environments.

What are the primary applications of cdc28 Antibody in research?

Cdc28 Antibody has been validated for multiple experimental applications, providing researchers with versatile options for studying Cdc28 protein:

• Western Blotting (WB): Enables detection of Cdc28 protein in cell lysates, allowing quantification of expression levels and post-translational modifications.

• Immunoprecipitation (IP): Facilitates isolation of Cdc28 and its protein complexes from cellular extracts, enabling studies of protein-protein interactions.

• Immunofluorescence (IF): Allows visualization of Cdc28 subcellular localization throughout the cell cycle or in response to various treatments.

• Enzyme-Linked Immunosorbent Assay (ELISA): Provides quantitative measurements of Cdc28 protein levels in samples .

For chromatin immunoprecipitation applications, researchers have successfully employed this antibody to study Cdc28 localization to approximately 200 genes, primarily those involved in cellular homeostasis functions .

How does cdc28 function in the yeast cell cycle?

Cdc28 (the yeast homolog of mammalian CDK1) serves as the master regulator of the cell cycle in Saccharomyces cerevisiae. Its activity is precisely controlled through several mechanisms:

• Association with specific cyclins: Cdc28 interacts with G1 cyclins (Cln1, Cln2, Cln3) to facilitate the G1 to S phase transition at a critical checkpoint known as Start.

• Interaction with S phase cyclins: Binding to Clb5 and Clb6 ensures proper coordination between DNA replication and cytokinesis.

• Regulation by M phase cyclins: Cdc28 forms complexes with Clb1 and Clb2 to control the G2 to M phase progression .

Beyond its canonical cell cycle functions, Cdc28 also plays a direct role in regulating basal transcription through both kinase-dependent and kinase-independent mechanisms . The ubiquitin-mediated proteolysis system involving Ubc9 and Cdc34 further regulates cyclin expression, highlighting the complex regulatory network maintaining cell cycle integrity .

How can I design ChIP experiments to study Cdc28 genomic localization?

When designing Chromatin Immunoprecipitation (ChIP) experiments to investigate Cdc28 genomic localization:

• Cell synchronization: Consider synchronizing yeast cells at specific cell cycle stages using methods such as α-factor arrest to examine cell-cycle-dependent binding patterns.

• Cross-linking optimization: Adjust formaldehyde concentration and cross-linking time (typically 10-20 minutes) to effectively capture transient Cdc28-DNA interactions.

• Target gene selection: Focus on genes involved in cellular homeostasis, such as PMA1 (plasma membrane proton pump), which has been identified as a direct target of Cdc28 .

• Controls:

  • Include input DNA samples

  • Use non-specific IgG for background measurement

  • Consider using cdc28 mutants (cdc28-as1 or cdc28-5M) as negative controls

  • Include known Cdc28-binding genes as positive controls

• Data analysis: For ChIP-seq experiments, utilize appropriate normalization methods and peak-calling algorithms designed for transcription factor binding site identification .

The literature indicates that Cdc28 localizes to at least 200 genes, primarily those involved in cellular homeostasis, making these promising targets for verification in your experimental system .

What experimental strategies can reveal Cdc28's role in transcriptional regulation?

Investigating Cdc28's function in transcriptional regulation requires multifaceted approaches:

• Chemical-genetic inhibition: Utilize the cdc28-as1 allele with the specific inhibitor 1-NM-PP1 to rapidly inhibit Cdc28 kinase activity and measure immediate effects on transcription. This approach has revealed that Cdc28 kinase activity is important for basal transcription .

• RNA Polymerase II occupancy: Perform ChIP experiments targeting Rpb1 (the largest subunit of RNA polymerase II) at specific genes like PMA1 to measure how Cdc28 activity affects polymerase recruitment and progression. Studies have shown that inhibiting Cdc28 kinase activity reduces Rpb1 levels at target genes .

• Genetic interaction screens: Cross cdc28 mutants with deletion libraries focusing on transcription-related genes. This approach has identified interactions between CDC28 and genes encoding kinases that phosphorylate the C-terminal domain of RNA polymerase II, such as KIN28 .

• Transcriptome analysis: Compare mRNA levels in wild-type versus cdc28 mutant strains, with and without kinase inhibitors, to distinguish between kinase-dependent and kinase-independent functions of Cdc28 in transcriptional regulation .

These combined approaches have revealed that Cdc28 not only activates cell-cycle-specific transcription factors during late G1 phase but also directly affects the basal transcription machinery through multiple mechanisms .

How do cdc28 mutants affect genome stability and what methods best detect these effects?

Cdc28 plays crucial roles in maintaining genome stability, with different experimental systems revealing distinct functions:

• Gross Chromosomal Rearrangement (GCR) assays: Studies have shown a direct correlation between Cdc28 activity and GCR formation rates. The hypomorphic alleles cdc28-as1 and cdc28-5M suppress GCR rates, while increased Cdc28 activity elevates GCR formation .

• Mutation rate analysis: When investigating mutation frequencies, use assays targeting CAN1, hom3-10, or lys2-Bgl loci. Notably, reduced Cdc28 activity does not affect the rate of point mutations but specifically suppresses gross chromosomal rearrangements .

• DNA damage sensitivity assays:

  • Acute exposure: Treat synchronized cells with DNA-damaging agents (HU, MMS, phleomycin) for short periods

  • Chronic exposure: Spot assays on plates containing various concentrations of DNA-damaging agents

  • Recovery analysis: Assess cell viability after damage and removal of the damaging agent

• Replication fork stability: Monitor replication fork progression and stability in cdc28 mutants using DNA combing or 2D gel electrophoresis, particularly after exposure to replication stress .

• Checkpoint activation: Analyze phosphorylation of checkpoint proteins (e.g., Rad53) and cell cycle progression by FACS in response to DNA damage in cdc28 mutant strains .

Research suggests that while Cdc28 is crucial for survival during DNA damage, it is not required for checkpoint activation, as cdc28-5M mutants efficiently arrest the cell cycle in response to DNA damage despite being highly sensitive to genotoxic agents .

What controls and considerations are essential when using 1-NM-PP1 with cdc28-as1 mutants?

When using the ATP analog 1-NM-PP1 with cdc28-as1 mutants for chemical-genetic inhibition experiments:

• Concentration optimization:

  • Use 200 nM as a starting point (reported IC50 for cdc28-as1)

  • Include dose-response experiments to determine the minimal effective concentration for your specific strain and experimental setup

  • Note that wild-type cells are resistant to at least 10 μM 1-NM-PP1

• Essential controls:

  • Wild-type strain (cdc28+) treated with the same 1-NM-PP1 concentration

  • Untreated cdc28-as1 cells to account for any phenotypes caused by the mutation itself

  • Time-course experiments to distinguish immediate versus secondary effects

  • Vehicle control (typically DMSO) to rule out solvent effects

• Pre-treatment considerations:

  • For cell cycle studies, synchronize cells and release them from arrest before 1-NM-PP1 addition

  • Short pre-treatment (e.g., 5 minutes) with 1-NM-PP1 before adding DNA-damaging agents can help distinguish Cdc28's direct roles in DNA damage response

• Genetic background effects:

  • Validate key findings in multiple independently derived isolates

  • Be aware that effects seen with cdc28-as1 should be confirmed with other cdc28 alleles when possible, as unexpected mutations might be present (e.g., documented A24C and T874C mutations in some strains)

• Temporal considerations:

  • The rapid inhibition provided by 1-NM-PP1 allows for precise temporal control

  • This approach can distinguish between Cdc28's roles in cell cycle initiation versus its direct functions in processes like transcriptional regulation

How should I interpret conflicting data about Cdc28's role in DNA damage response?

When faced with seemingly contradictory findings regarding Cdc28's function in DNA damage response:

• Distinguish between different types of DNA damage:

  • Hydroxyurea (HU): Primarily causes replication stress

  • Methyl methanesulfonate (MMS): Alkylates DNA, causing replication blocks

  • Phleomycin: Induces double-strand breaks

  • Different cdc28 alleles may show varying sensitivities to these agents

• Differentiate between chronic and acute exposure effects:

  • Chronic exposure: cdc28 mutants show increased sensitivity in spot assays

  • Acute exposure: cdc28-as1 mutants demonstrate normal survival rates when Cdc28 is inhibited after cells have passed Start

• Consider cell cycle stage-specific functions:

  • G1 phase: Cdc28 is required for Start activation and subsequent cell cycle entry

  • S phase: Cdc28 may have roles in stabilizing stalled replication forks

  • G2/M: Cdc28 activity regulates DNA damage checkpoint recovery

• Analyze checkpoint versus recovery functions:

  • Evidence indicates that Cdc28 is not required for checkpoint activation (cdc28-5M mutants efficiently arrest the cell cycle in response to MMS)

  • Cdc28 may be involved in recovery from checkpoint activation, similar to phosphatases like Ptc2, Ptc3, and Pph3

• Separate direct versus indirect effects:

  • Direct roles: Immediate consequences of Cdc28 inhibition

  • Indirect roles: Secondary effects due to transcriptional or other downstream changes

Research suggests that Cdc28's primary role in the DNA damage response is not in checkpoint activation (unlike Rad53) but rather in maintaining cell viability during damage and potentially in recovery from checkpoint arrest .

What strain considerations are important when studying cdc28 in yeast?

When selecting or constructing yeast strains for cdc28 studies:

• Background strain selection:

  • S288c derivatives (e.g., RDKY3615) provide a well-characterized genetic background with minimal unexpected phenotypes

  • Ensure genetic compatibility with your experimental system and markers

• Key mutant alleles for chemical-genetic studies:

  • cdc28-as1: Contains an enlarged ATP-binding pocket, allowing specific inhibition by 1-NM-PP1

  • Note potential sequence variations: documented strains may contain A24C and T874C mutations (resulting in Thr8Pro and Ile291Thr substitutions) that do not affect 1-NM-PP1 sensitivity

• Alternative cdc28 alleles:

  • cdc28-5M: Temperature-sensitive allele useful for constitutive reduction in Cdc28 activity

  • Construction typically involves PCR amplification of the coding sequence along with selectable markers (TRP1, HIS3) for integration

• Genetic interaction studies:

  • Consider double mutants with genes involved in:

    • RAD6 pathway

    • Paf1 complex

    • Ccr4-NOT complex

    • RNA polymerase II C-terminal domain kinases (e.g., KIN28)

• Marker considerations:

  • Common selectable markers include TRP1, HIS3, and NAT-NT1 (nourseothricin resistance)

  • When studying genomic instability, carefully select marker positions to avoid interference with gross chromosomal rearrangement (GCR) assays

The choice of genetic background and specific cdc28 alleles should be guided by your experimental questions, as different alleles may reveal distinct aspects of Cdc28 function .

How can I distinguish between Cdc28's cell-cycle-dependent and independent functions?

Differentiating between Cdc28's canonical cell cycle roles and its direct functions in processes like transcription requires strategic experimental design:

• Cell cycle synchronization approaches:

  • α-factor arrest (G1 phase): Release cells and allow them to pass Start before inhibiting Cdc28 to separate Start-dependent from other functions

  • Nocodazole arrest (G2/M): Study Cdc28 functions in mitosis independently of its role in G1/S transition

  • Hydroxyurea arrest (early S phase): Examine Cdc28's role during DNA replication

• Chemical-genetic strategies:

  • Use cdc28-as1 with timed 1-NM-PP1 addition to inhibit kinase activity at specific cell cycle stages

  • Analyze immediate versus delayed phenotypes to distinguish direct from indirect effects

• Genetic separation-of-function:

  • Exploit specific cdc28 alleles that differentially affect distinct functions

  • Analyze epistatic relationships with mutations in cell cycle versus transcription pathways

• Target gene selection:

  • Cell-cycle regulated genes: MCM factors, cyclins

  • Constitutively expressed homeostasis genes: PMA1 (plasma membrane proton pump)

  • Compare Cdc28's effects on both gene categories

• Methodological approach:

  • ChIP-seq to identify genome-wide binding patterns across the cell cycle

  • RNA-seq to distinguish transcriptional effects at different cycle stages

  • Combine with cell cycle markers to correlate Cdc28 activity with specific phases

Research has revealed that Cdc28 has a direct role in regulating basal transcription that is distinct from its function in activating cell-cycle-specific transcription factors during late G1 phase, with evidence indicating both kinase-dependent and kinase-independent mechanisms .

What methodological considerations are important when studying Cdc28's interaction with RNA polymerase II?

When investigating how Cdc28 affects RNA polymerase II activity and transcription:

• ChIP protocol optimization:

  • Focus on the largest RNA polymerase II subunit (Rpb1) as a target for immunoprecipitation

  • Include appropriate controls for background signal and antibody specificity

  • Consider using tagged versions of Rpb1 if direct antibodies show variability

• Gene target selection:

  • Include constitutively expressed genes like PMA1 (plasma membrane proton pump)

  • Add housekeeping genes like SSE1 for comparison

  • Note that different genes may show distinct responses to Cdc28 inhibition

• Data interpretation challenges:

  • Increased Rpb1 levels at certain genes (e.g., PMA1) in untreated cdc28-as1 and kin28-as mutants compared to wild-type cells may indicate elongation defects rather than enhanced transcription

  • Verify with mRNA level measurements, as increased polymerase occupancy does not always correlate with higher transcript levels

• Experimental design considerations:

  • Study genetic interactions between CDC28 and genes encoding kinases that phosphorylate the C-terminal domain of RNA polymerase II, such as KIN28

  • Test double mutants (e.g., kin28-as cdc28-as1) to reveal potential redundancy or synergy in transcriptional regulation

• Kinase inhibition approach:

  • Treat cells with 1-NM-PP1 to inhibit cdc28-as1 and/or kin28-as kinase activity

  • Monitor effects on Rpb1 levels at target genes

  • Note that both Cdc28 and Kin28 kinase activities appear important for maintaining proper RNA polymerase II levels at certain genes

Research has shown that treatment of cdc28-as1 and kin28-as single mutants and kin28-as cdc28-as1 double mutants with 1-NM-PP1 strongly reduces Rpb1 levels at genes like PMA1, demonstrating that the kinase activities of both proteins are important for RNA polymerase II regulation .

What factors explain the correlation between Cdc28 activity and genome instability?

The relationship between Cdc28 activity and genomic instability is complex and multifaceted:

Understanding these complex relationships requires integrating data from multiple experimental approaches and considering both direct and indirect effects of Cdc28 activity on genome maintenance pathways .

How should researchers select appropriate antibody conjugates for different experimental applications?

Selection of the optimal cdc28 Antibody conjugate depends on your specific experimental requirements:

When selecting between conjugate options:

• Consider signal amplification needs:

  • Direct conjugates (HRP, fluorophores) offer simplicity but limited amplification

  • For low-abundance targets, consider using unconjugated primary antibody with signal-enhancing detection systems

• Evaluate potential cross-reactivity:

  • m-IgG Fc BP-HRP and m-IgGκ BP-HRP bundles offer alternative detection strategies that may reduce non-specific binding

  • Select based on the composition of your experimental system

• Technical considerations:

  • The 200 μg/ml concentration is standard for most conjugates

  • Agarose conjugates (AC) are supplied at 500 μg/ml with 25% agarose for immunoprecipitation applications

  • Factor in stability, storage requirements, and handling characteristics

• Experimental validation:

  • Include appropriate controls to verify specificity regardless of conjugate choice

  • Consider testing multiple conjugate formats if encountering technical difficulties

The availability of multiple conjugated forms enables researchers to optimize detection methods based on their specific experimental requirements, instrumentation, and detection sensitivity needs .